Phase 3 Data: Sonelokimab May Be Effective for HS; One Trial Shows High Placebo Rate
MoonLake Immunotherapeutics’s sonelokimab hit all endpoints in patients with moderate-to-severe hidradenitis suppurativa (HS), according to the Week 16 results of the Phase 3 VELA-1 and VELA-2 trials.